Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.

ABSTRACT:

Background

Based on current evidence, recent guidelines of the National Institute of Health, USA indicated the use of remdesivir and dexamethasone for the treatment of COVID-19 patients with mild-moderate disease, not requiring high-flow oxygen. No therapeutic agent directed against the immunologic pathogenic mechanisms related to the cytokine release syndrome complicating the disease was indicated.

Objectives

The purpose of this review was to assess the clinical impact of different therapies for COVID-19; thus, helping to identify the optimal management of the disease. To explain the rationale for the different therapeutic approaches, the characteristics of SARS-CoV-2, the pathogenesis of COVID-19, and the immune response triggered by SARS-CoV-2 infection were reported.

SUBMITTER: Cantini F 

PROVIDER: S-EPMC7568461 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature